Core Points - A class action securities lawsuit has been filed against DexCom, Inc. to recover losses for shareholders affected by alleged securities fraud between January 8, 2024, and September 17, 2025 [2] - The lawsuit alleges that DexCom made unauthorized material design changes to its glucose monitoring products, the G6 and G7, which rendered them less reliable and posed health risks to users [3] - The complaint claims that the defendants overstated the enhancements and reliability of the G7 device while downplaying the severity of the issues, leading to increased regulatory scrutiny and potential financial harm [3] Case Details - The lawsuit outlines that DexCom's design changes to the G6 and G7 were not authorized by the U.S. Food and Drug Administration [3] - It is alleged that these changes compromised the accuracy of glucose readings, which is critical for users relying on these devices for health management [3] - The complaint indicates that the public statements made by the defendants were materially false and misleading throughout the relevant period [3] Next Steps - Shareholders who suffered losses in DexCom stock during the specified timeframe are encouraged to seek information about their rights to recovery [4] - Participation in the recovery process is stated to be at no cost or obligation to the shareholders [4] Firm Background - Levi & Korsinsky LLP is highlighted as a nationally-recognized securities litigation firm with a strong track record in securing recoveries for shareholders [5] - The firm has been ranked among the top securities litigation firms in the United States for seven consecutive years [5] - Levi & Korsinsky has extensive experience in complex securities litigation, with a dedicated team to support clients [5]

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of securities of Stride, Inc. for the period between October 22, 2024, and October 28, 2025, due to alleged misleading statements and omissions regarding the company's products and services [1][5]. Group 1: Lawsuit Details - The class action lawsuit claims that Stride made misleading statements about its products and services, which were designed to help learners reach their full potential [5]. - Allegations include that Stride inflated enrollment numbers, cut staff costs beyond statutory limits, ignored compliance requirements, and lost existing and potential enrollments [5]. Group 2: Participation Information - Investors who purchased Stride securities during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To join the class action, investors can visit the provided link or contact the law firm directly for more information [3][6]. Group 3: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company [4]. - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [4].

Core Points - Rosen Law Firm is reminding KBR, Inc. investors of the November 18, 2025 deadline to join a securities class action lawsuit related to the company's performance during the Class Period from May 6, 2025, to June 19, 2025 [1][2] Group 1: Class Action Details - Investors who purchased KBR securities during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and potential lead plaintiffs must move the Court by November 18, 2025 [3] - The lawsuit alleges that KBR made materially false and misleading statements regarding its partnership with HomeSafe and the ability to fulfill the Global Household Goods Contract, leading to investor damages when the truth was revealed [5] Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements in recovering hundreds of millions for investors [4] - The firm has been recognized for its performance in securities class action settlements, including being ranked No. 1 by ISS Securities Class Action Services in 2017 and securing over $438 million for investors in 2019 [4]

Core Viewpoint - A class action lawsuit has been filed against Synopsys, Inc. for securities fraud following a significant stock drop due to alleged violations of federal securities laws [1][3]. Group 1: Lawsuit Details - Investors have until December 30, 2025, to request to lead the case in the U.S. District Court for the Northern District of California [3]. - The lawsuit claims violations under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [3]. Group 2: Company Performance - Synopsys provides design automation software and has seen its Design IP segment grow from 25% of revenue in 2022 to 31% in 2024 [4]. - The company reported Q3 2025 results showing a 7.7% year-over-year decline in Design IP revenue to $425.9 million and a 43% year-over-year decline in net income to $242.5 million [6]. Group 3: Market Reaction - Following the Q3 2025 results, Synopsys stock fell nearly 36%, from $604.37 per share to $387.78 per share [6]. - The decline was attributed to customers requiring more customization for IP components, impacting the business model and economics of the Design IP segment [5][6].

MLTX SECURITIES ALERT: BFA Law Notifies MoonLake Immunotherapeutics Investors of Important December 15 Securities Class Action DeadlineNovember 17, 2025 3:18 PM EST | Source: Bleichmar Fonti & AuldNew York, New York--(Newsfile Corp. - November 17, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against MoonLake Immunotherapeutics (NASDAQ: MLTX) and certain of the Company's senior executives for potential violations of the federal securitie ...

Core Viewpoint - A class action lawsuit has been filed against Inspire Medical Systems, Inc. for securities fraud following a significant stock drop due to alleged violations of federal securities laws [2][4]. Company Overview - Inspire Medical Systems, Inc. specializes in developing and manufacturing implantable medical devices for the treatment of sleep apnea, with its latest product being the Inspire V, which received FDA approval on August 2, 2024 [5]. Allegations and Issues - The lawsuit claims that Inspire misled investors by assuring them that all necessary steps were taken for the launch of Inspire V, which was supposed to meet high demand. However, the company failed to adequately prepare clinicians and payors, leading to significant delays in adoption [6][7]. - The launch of Inspire V faced an "elongated timeframe," resulting in a reduction of the 2025 earnings per share guidance by over 80%. Contributing factors included incomplete training at implanting centers and poor demand due to excess inventory of older devices [8]. Stock Performance - Following the announcement of the delays, Inspire's stock price plummeted by $42.04 per share, a decrease of more than 32%, dropping from $129.95 on August 4, 2025, to $87.91 on August 5, 2025 [9].

Core Viewpoint - Ardent Health, Inc. is under investigation for potential violations of federal securities laws following a significant drop in its stock price, which fell over 33% after the company reported disappointing Q3 2025 financial results [1][3][4]. Financial Performance - In Q3 2025, Ardent reported a $43 million decrease in revenue due to "hindsight evaluations of historical collection trends" [4]. - The company also increased its professional liability reserves by $54 million, citing "adverse prior period claim developments" related to claims from 2019 to 2022 and broader industry trends [4]. Stock Market Reaction - Following the financial disclosures on November 12, 2025, Ardent's stock price plummeted over 33% during trading on November 13, 2025 [4]. Legal Implications - Bleichmar Fonti & Auld LLP has initiated an investigation into Ardent Health, encouraging investors to seek additional information regarding potential legal options [1][5].

Core Viewpoint - A class action lawsuit has been filed against Stride, Inc. for securities fraud, following significant stock drops attributed to alleged violations of federal securities laws [2][4]. Company Overview - Stride, Inc. is an education technology company that provides an online platform to students across the U.S. [5]. Allegations and Stock Impact - The lawsuit claims that Stride inflated enrollment numbers by retaining "ghost students" and ignored compliance requirements, leading to poor customer experiences and higher withdrawal rates [5]. - On September 14, 2025, a report of the fraud complaint caused Stride's stock to drop by $18.60, or over 11%, from $158.36 to $139.76 per share [6]. - Following an admission of poor customer experience on October 28, 2025, Stride's stock plummeted by $83.48, or more than 54%, from $153.53 to $70.05 per share [7]. Legal Proceedings - Investors have until January 12, 2026, to request to lead the case in the U.S. District Court for the Eastern District of Virginia [4]. - The lawsuit is filed under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [4]. Investor Actions - Investors are encouraged to seek additional information and may have legal options available [3][8].

Core Viewpoint - Beyond Meat, Inc. is under investigation for potential violations of federal securities laws following a significant drop in its stock price, attributed to concerns over the valuation of its long-lived assets and an impending non-cash impairment charge [2][4][5]. Group 1: Stock Performance and Investigation - Beyond Meat's stock plummeted by approximately 23% on October 24, 2025, from $2.84 to $2.185 per share after the company announced expectations of a material non-cash impairment charge related to its long-lived assets [6]. - The company delayed its earnings announcement for the third quarter of 2025 on November 3, 2025, due to the need for additional time to complete the impairment review, which further contributed to a decline in stock value on that trading day [7]. Group 2: Legal Actions and Implications - Bleichmar Fonti & Auld LLP is leading the investigation into whether Beyond Meat inflated the value of certain long-lived assets, which may have misled investors [5]. - Investors in Beyond Meat are encouraged to seek legal options and may submit their information to the law firm for potential class action participation [8].

Core Viewpoint - A class action lawsuit has been filed against James Hardie Industries plc and certain senior executives for securities fraud following a significant stock drop attributed to potential violations of federal securities laws [1][3]. Company Overview - James Hardie Industries plc is a producer and marketer of high-performance fiber cement building solutions, primarily used in external siding for the residential building industry in the United States and Canada [4]. Allegations of Fraud - The lawsuit claims that James Hardie misrepresented the strength and momentum of its North American fiber cement segment, asserting that sales were driven by sustainable customer demand rather than inventory loading by channel partners, which is indicative of fraudulent channel stuffing [5]. Stock Performance and Impact - On August 19, 2025, James Hardie reported a 12% decline in North American fiber cement sales, revealing that destocking efforts by customers were impacting sales, leading to a stock price drop of $9.79 per share, or over 34%, from $28.43 to $18.64 within a day [6].